{"denoms":[{"counts":[{"groupId":"BG000","value":"55"},{"groupId":"BG001","value":"69"},{"groupId":"BG002","value":"199"},{"groupId":"BG003","value":"23"},{"groupId":"BG004","value":"15"},{"groupId":"BG005","value":"361"}],"units":"Participants"}],"groups":[{"description":"Patients receive busulfan IV over 2 hours every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.\n\nbusulfan: Given IV\n\ncyclophosphamide: Given IV","id":"BG000","title":"BuCy"},{"description":"Patients receive cyclophosphamide IV over 2 hours on days -5 and -4 and total-body irradiation (TBI) twice daily on days -3 to -1.\n\ncyclophosphamide: Given IV\n\ntotal-body irradiation: Given twice daily for 3 days","id":"BG001","title":"CyTBI"},{"description":"Patients receive fludarabine IV over 30 minutes on days -6 to -2 and melphalan IV over 1 hour on days -3 and -2.\n\nfludarabine phosphate: Given IV\n\nmelphalan: Given IV","id":"BG002","title":"FluMel"},{"description":"Patients receive etoposide IV over 26 hours beginning on day -5, cyclophosphamide IV over 2 hours on day -4, and TBI twice daily on days -3 to -1.\n\ncyclophosphamide: Given IV\n\netoposide: Given IV\n\ntotal-body irradiation: Given twice daily for 3 days","id":"BG003","title":"VpCyTBI"},{"description":"Patients receive cyclophosphamide IV over 2 hours on days -5 to -2 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -3. OR Patients receive cyclophosphamide IV over 24 hours, carboplatin IV over 24 hours, and thiotepa IV over 24 hours on days -7 to -4. OR Patients receive fludarabine IV over 30 minutes on days -5 to -1 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -2. OR Patients receive cyclophosphamide IV over 2 hours on days -5 and -4, TBI twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4-8 hours on days -3 to -1.\n\nOR Patients receive busulfan IV over 2 hours every 6 hours and anti-thymocyte globulin IV over 4-8 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.","id":"BG004","title":"Other"},{"description":"Total of all reporting groups","id":"BG005","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"6","upperLimit":"59","value":"46"},{"groupId":"BG001","lowerLimit":"4","upperLimit":"50","value":"28"},{"groupId":"BG002","lowerLimit":"6","upperLimit":"68","value":"48"},{"groupId":"BG003","lowerLimit":"8","upperLimit":"55","value":"37"},{"groupId":"BG004","lowerLimit":"6","upperLimit":"52","value":"41"},{"groupId":"BG005","lowerLimit":"4","upperLimit":"68","value":"44"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"80"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"139"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"119"},{"groupId":"BG003","value":"16"},{"groupId":"BG004","value":"11"},{"groupId":"BG005","value":"222"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"53"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"188"},{"groupId":"BG003","value":"20"},{"groupId":"BG004","value":"12"},{"groupId":"BG005","value":"341"}]}],"title":"Non-Hispanic White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"12"}]}],"title":"Non-Hispanic African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"3"}]}],"title":"Non-Hispanic Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"3"}]}],"title":"Hispanic, White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"}]}],"title":"Non-Hispanic Native Am"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"55"},{"groupId":"BG001","value":"69"},{"groupId":"BG002","value":"199"},{"groupId":"BG003","value":"23"},{"groupId":"BG004","value":"15"},{"groupId":"BG005","value":"361"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"89"},{"groupId":"BG003","value":"13"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"147"}],"title":"Acute myeloid leukemia"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"54"}],"title":"Acute lymphoblastic leukemia"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"37"}],"title":"Chronic myeloid or lymphocytic leukemia"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"56"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"72"}],"title":"Hodgkin or Non-Hodgkin lymphoma or multiple myeloma"},{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"23"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"43"}],"title":"Myelodysplastic syndrome or myeloproliferative disorder"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"7"}],"title":"Severe Aplastic anemia"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"1"}],"title":"Solid Tumor"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Disease","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"73"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"161"}],"title":"Standard"},{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"126"},{"groupId":"BG003","value":"13"},{"groupId":"BG004","value":"11"},{"groupId":"BG005","value":"200"}],"title":"High"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Risk group","unitOfMeasure":"Participants"}]}